Cross-reactivity between dengue virus and SARS-CoV-2 antibodies: Confirmation study using specimens from dengue-infected patients before the COVID-19 pandemic

The simultaneous occurrence of the COVID-19 pandemic and a dengue outbreak has posed significant challenges for governments and medical personnel in dengue-endemic countries like Indonesia. Several studies in dengue-endemic countries have reported cases of misdiagnosis between COVID-19 and dengue. T...

Full description

Saved in:
Bibliographic Details
Published in:Heliyon 2024-11, Vol.10 (21), p.e39099, Article e39099
Main Authors: Churrotin, Siti, Amarullah, Ilham Harlan, Fitria, Anisa Lailatul, Khairunisa, Siti Qamariyah, Yamani, Laura Navika, Kameoka, Masanori, Anggraeni, Novi, Nurhariansyah, Robby, Husada, Dominicus, Wungu, Citrawati Dyah Kencono
Format: Article
Language:English
Subjects:
Antibody
blood serum
COVID-19
COVID-19 infection
cross reaction
Cross-reactivity
Dengue
Dengue virus
enzyme-linked immunosorbent assay
health care workers
humans
Indonesia
pandemic
rapid methods
risk
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The simultaneous occurrence of the COVID-19 pandemic and a dengue outbreak has posed significant challenges for governments and medical personnel in dengue-endemic countries like Indonesia. Several studies in dengue-endemic countries have reported cases of misdiagnosis between COVID-19 and dengue. Therefore, it is crucial to evaluate the potential cross-reactivity between SARS-CoV-2 antibodies and dengue. This study aimed to confirm the serological cross-reaction between dengue virus and SARS-CoV-2 in Surabaya, East Java, which is a highly dengue-endemic city in Indonesia. In total, 238 serum samples with confirmed dengue that were collected before the emergence of COVID-19 were tested to detect the presence of reacting IgG and IgM antibodies (Abs) against SARS-CoV-2 via a rapid detection test (RDT) and enzyme-linked immunosorbent assay (ELISA). Samples from patients with dengue infection collected during the pandemic, from healthy volunteers predating the pandemic, and from patients with COVID-19 were used for comparison. Few (6.7 %) of the pre-COVID-19 dengue Ab-positive serum samples showed reactive on SARS-CoV-2 in the RDT, with significantly lower IgG and IgM levels detected in ELISA compared with the dengue samples collected during the pandemic and the COVID-19 samples (P 
ISSN:2405-8440
2405-8440
DOI:10.1016/j.heliyon.2024.e39099